ライフサイエンスコーパス: complement-dependent cytotoxicity

1 a strong negative impact on C1q binding and complement-dependent cytotoxicity.

2 athogens by mediating antibody-dependent and complement-dependent cytotoxicity.

3 antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

4 ment component C1q, and inability to mediate complement-dependent cytotoxicity.

5 rior ability of the bispecific Abs to induce complement-dependent cytotoxicity.

6 NK cell death occurs via both antibody- and complement-dependent cytotoxicity.

7 nificant enhancement of daratumumab-mediated complement-dependent cytotoxicity.

8 antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

9 d the surface of carcinoma cells and induced complement-dependent cytotoxicity.

10 Treg are resistant to alemtuzumab-mediated, complement-dependent cytotoxicity.

11 iated Ab-dependent cellular cytotoxicity, or complement-dependent cytotoxicity.

12 ntibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity.

13 ne antihuman lymphocyte serum active through complement-dependent cytotoxicity.

14 CD20 molecules and impair rituximab-mediated complement-dependent cytotoxicity.

15 to identify inhibitors of NMO-IgG-dependent, complement-dependent cytotoxicity.

16 otoxicity compared with veltuzumab but lacks complement-dependent cytotoxicity.

17 pendent cellular toxicity, neither displayed complement-dependent cytotoxicity.

18 When screened by complement-dependent cytotoxicity, 46% of the patients w

19 mechanisms to delete target cells, including complement-dependent cytotoxicity, Ab-dependent cellular

20 ation of tumor cell signaling, activation of complement-dependent cytotoxicity, Ab-dependent cellular

21 antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities of the anti

22 Ab-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities.

23 Ab-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities.

24 ral blood mononuclear cells, and had minimal complement-dependent cytotoxicity activity similar to th

25 A complete loss of complement-dependent cytotoxicity activity was seen with

26 lt in a dramatic increase in C1q binding and complement-dependent cytotoxicity activity.

27 ts exhibiting an increase in C1q binding and complement-dependent cytotoxicity activity.

28 addition, a GD3 antibody is shown to induce complement-dependent cytotoxicity against cells expressi

29 ntibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity against primary CLL ce

30 t significantly increased rituximab-mediated complement-dependent cytotoxicity against primary tumor

31 , an SSEA-4-specific mAb was found to induce complement-dependent cytotoxicity against SSEA-4(hi) GBM

32 ts with positive antihuman globulin-enhanced complement dependent cytotoxicity (AHG-CDC) crossmatches

33 -titer positive antihuman globulin-enhanced, complement-dependent cytotoxicity (AHG-CDC) cross-matche

34 phocyte cytotoxicity (antiglobulin-enhanced, complement-dependent cytotoxicity [AHG-CDC]) or assays (

35 It was shown that complement-dependent cytotoxicity and Ab-dependent cellu

36 cells are less susceptible to mATG-mediated complement-dependent cytotoxicity and ADCC.

37 Preformed Nabs were evaluated using both complement-dependent cytotoxicity and antibody (IgM and

38 IgG into F(ab')2 and Fc fragments inhibiting complement-dependent cytotoxicity and antibody-dependent

39 Preclinical data suggest improved complement-dependent cytotoxicity and antibody-dependent

40 prostate cancer cell death, it also mediates complement-dependent cytotoxicity and antibody-dependent

41 Trx activity, with significant loss in both complement-dependent cytotoxicity and antibody-dependent

42 Rituximab mediates complement-dependent cytotoxicity and antibody-dependent

43 onal antibody rituximab in vitro, increasing complement-dependent cytotoxicity and antibody-mediated

44 ined by positive results on SPA but negative complement-dependent cytotoxicity and flow cytometry cro

45 Circulating alloAb levels were quantified by complement-dependent cytotoxicity and flow cytometry.

46 ridge to HT had standard anti-human globulin complement-dependent cytotoxicity and retrospective flow

47 A class II alloantibodies (aAb) using direct complement-dependent cytotoxicity and several sensitive

48 to percent panel-reactive antibody (PRA; by complement-dependent cytotoxicity) and anti-MICA antibod

49 ng antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependen

50 tibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and antiinflammatory

51 ecognized GD2-positive tumor cells, mediated complement-dependent cytotoxicity, and exhibited protect

52 dy-dependent cellular cytotoxicity, mediates complement-dependent cytotoxicity, and induces apoptosis

53 ependent cell-mediated cytotoxicity, but not complement-dependent cytotoxicity, and inhibits prolifer

54 ecutive patients after exclusions yielded 94 complement-dependent cytotoxicity anti-human globulin cr

55 portion of ISB 1442 is engineered to enhance complement dependent cytotoxicity, antibody dependent ce

56 ugh a variety of immune-mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent ce

57 ages diverse mechanisms of action, including complement-dependent cytotoxicity, antibody-dependent ce

58 Complement-dependent cytotoxicity, antibody-dependent ce

59 LL cells, we show that direct cell death and complement-dependent cytotoxicity are greatest with GA10

60 nt predictor of graft rejection highlighting complement-dependent cytotoxicity as a key process opera

61 human IgG2 confer biological activity in the complement-dependent cytotoxicity assay in which the wil

62 The commonly performed complement-dependent cytotoxicity assay is insensitive c

63 e representative antibody-positive sera in a complement-dependent cytotoxicity assay with cultured me

64 ive antibody level, determined by use of the complement-dependent cytotoxicity assay, of 77+/-19% or

65 dy production was determined serially with a complement-dependent cytotoxicity assay.

66 ific B cell hybridomas in a flow cytometric, complement-dependent cytotoxicity assay.

67 Complement-dependent cytotoxicity assays were performed

68 detected by the PRA-STAT ELISA system and by complement-dependent cytotoxicity assays.

69 both Ab-dependent cellular cytotoxicity and complement-dependent cytotoxicity assays.

70 The blockers did not affect complement-dependent cytotoxicity caused by anti-GD3 ant

71 More than 2,000 complement dependent cytotoxicity (CDC) and 200 flow cro

72 C were related to loss in drug potency via a complement dependent cytotoxicity (CDC) bioassay.

73 In this study, we sought to test the role of complement dependent cytotoxicity (CDC) immune effector

74 n proposed that IgG may confer resistance to complement dependent cytotoxicity (CDC), a conventional

75 enhance antibody hexamerization and thereby complement dependent cytotoxicity (CDC).

76 s of neonatal Fc receptor (FcRn) binding and complement-dependent cytotoxicity (CDC) activity.

77 t trastuzumab nor tras + pert, elicit potent complement-dependent cytotoxicity (CDC) against high HER

78 induced mouse antibodies mediated effective complement-dependent cytotoxicity (CDC) against the pros

79 ansplant recipients who have positive B-cell complement-dependent cytotoxicity (CDC) along with posit

80 equire NMO-IgG effector function to initiate complement-dependent cytotoxicity (CDC) and antibody-dep

81 85(her2/neu) kinase (ERBB2) but also trigger complement-dependent cytotoxicity (CDC) and antibody-dep

82 plement cascade induces tumor cell lysis via complement-dependent cytotoxicity (CDC) and attracts and

83 ent cellular phagocytosis (ADCP), as well as complement-dependent cytotoxicity (CDC) and direct cell

84 orin-4 (AQP4) on astrocytes, which initiates complement-dependent cytotoxicity (CDC) and inflammation

85 -IgG) to astrocyte aquaporin-4 (AQP4) causes complement-dependent cytotoxicity (CDC) and inflammation

86 Both the complement-dependent cytotoxicity (CDC) assay (class I)

87 Using flow cytometry and complement-dependent cytotoxicity (CDC) assays, we have

88 A third strategy used complement-dependent cytotoxicity (CDC) by treating the

89 mplement, which may avoid the false-positive complement-dependent cytotoxicity (CDC) crossmatch tests

90 using bead-based assay as an add-on test to complement-dependent cytotoxicity (CDC) crossmatch with

91 Complement-dependent cytotoxicity (CDC) has been suggest

92 we tested whether EMT confers resistance to complement-dependent cytotoxicity (CDC) in lung cancer c

93 Complement-dependent cytotoxicity (CDC) is a primary mec

94 Although AQP4-IgG-driven complement-dependent cytotoxicity (CDC) is critical for

95 pendent cell-mediate phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC) mechanisms.

96 assessed complement binding, deposition, and complement-dependent cytotoxicity (CDC) of 27 known IgG

97 effective than rituximab (RTX) in promoting complement-dependent cytotoxicity (CDC) of B cells via t

98 mab and ofatumumab (OFA), efficiently induce complement-dependent cytotoxicity (CDC) of CD20(+) B cel

99 Antibody binding and complement-dependent cytotoxicity (CDC) of D-/R- and D+/

100 y-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) of HIV-1-infecte

101 oward neoplastic cells that can kill without complement-dependent cytotoxicity (CDC) or antibody-depe

102 tibodies has been performed using cell-based complement-dependent cytotoxicity (CDC) techniques.

103 ixing and clinically relevant based upon the complement-dependent cytotoxicity (CDC) test.

104 m was used to measure IgM/IgG binding to and complement-dependent cytotoxicity (CDC) to cells from WT

105 n to regulate numerous biologic processes on complement-dependent cytotoxicity (CDC) was investigated

106 h innate and adaptive immunity, is executing complement-dependent cytotoxicity (CDC) with its C5b-9 p

107 correlated with the extent of cell lysis by complement-dependent cytotoxicity (CDC), and a peptide c

108 ect antiproliferative and apoptotic effects, complement-dependent cytotoxicity (CDC), and antibody-de

109 dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis h

110 T- and B-cell complement-dependent cytotoxicity (CDC), flow cytometric

111 AQP4-IgG binding to aquaporin-4 causes complement-dependent cytotoxicity (CDC), leading to infl

112 contribute to Ab efficacy against cancer is complement-dependent cytotoxicity (CDC).

113 ficiently by C1q, deposit C3b, and result in complement-dependent cytotoxicity (CDC).

114 ing to the resistance of tumor cells against complement-dependent cytotoxicity (CDC).

115 ns that stimulated IgG hexamer formation and complement-dependent cytotoxicity (CDC).

116 otoxicity (ADCC), complement deposition, and complement-dependent cytotoxicity (CDC).

117 tes using the innate immune system including complement-dependent cytotoxicity (CDC).

118 ein 70, plays a role in cell protection from complement-dependent cytotoxicity (CDC).

119 mechanisms that support their resistance to complement-dependent cytotoxicity (CDC).

120 b-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

121 ncer therapy depends in part on induction of complement-dependent cytotoxicity (CDC).

122 by monoclonal antibodies, which act through complement-dependent cytotoxicity (CDC).

123 Disadvantages inherent to complement-dependent cytotoxicity cross-match (CDC XM) m

124 Six/eight combinations for sHI patients were complement-dependent cytotoxicity cross-match negative.

125 r for the highest risk group with a positive complement-dependent cytotoxicity crossmatch (CDC XM) be

126 splants from deceased donors with a negative complement-dependent cytotoxicity crossmatch (XM) was pe

127 Physical crossmatch (PXM), including complement-dependent cytotoxicity crossmatch and flow cy

128 re allele was a poor predictor of a positive complement-dependent cytotoxicity crossmatch, with a pos

129 (DSZ) strategies in patients with a negative complement-dependent cytotoxicity crossmatch.

130 The antigens identified to produce positive complement-dependent cytotoxicity crossmatches (XMs; >20

131 en bead (SAB) assay-defined DSA but negative complement-dependent cytotoxicity crossmatches were enro

132 ell flow cytometry (FXM) versus conventional complement-dependent cytotoxicity (CXM) in consecutive p

133 in the elicitation of dramatically enhanced complement-dependent cytotoxicity, Fc receptor function,

134 y-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity from IgG antibodies in

135 homa cell lines tested, as well as increased complement-dependent cytotoxicity in 1 of 3 cell lines,

136 There was evidence of complement-dependent cytotoxicity in several patients.

137 ody-dependent cell-mediated cytotoxicity and complement-dependent-cytotoxicity in GPC3-positive cance

138 ody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, is desirable for ther

139 renchyma, meningeal B cell accumulation, and complement-dependent cytotoxicity mediated by antineuron

140 Patients with a complement-dependent cytotoxicity negative and flow cyto

141 ected patients who underwent ABO-compatible, complement-dependent cytotoxicity-negative crossmatch ki

142 fluorescence intensity [MFI] > 3000) with a complement-dependent cytotoxicity-negative crossmatch, w

143 ed to rituximab-mediated growth reduction or complement-dependent cytotoxicity nor underwent apoptosi

144 Anti-CCL20 Ab-mediated, complement-dependent cytotoxicity occurred when the Ab b

145 The resulting IgG2a response mediated complement-dependent cytotoxicity of a LeY-expressing hu

146 l-dependent cytotoxicity but did not mediate complement-dependent cytotoxicity of HMW-MAA(+) melanoma

147 wn by binding of ch 14.18 to tumor cells and complement-dependent cytotoxicity of posttreatment sera

148 at human MAbs against B5 can potently direct complement-dependent cytotoxicity of vaccinia virus-infe

149 the ability of col(V) immune serum to induce complement-dependent cytotoxicity only in the epithelial

150 When analyzed by complement-dependent cytotoxicity, only 2 of 15 BOS+ pat

151 ivity kill GcSTn-expressing human tumors via complement-dependent cytotoxicity or antibody-dependent

152 cell donor cross-matches using antiglobulin complement-dependent cytotoxicity or flow cytometry woul

153 tive antibody [cPRA] class I and/or II >99%, complement-dependent cytotoxicity panel reactive antibod

154 cytes, or polymorphonuclear cells as well as complement-dependent cytotoxicity positively correlated

155 ls, polymorphonuclear cell-mediated ADCC and complement-dependent cytotoxicity required higher EGFR e

156 ng scIgG preparation also generated positive complement-dependent cytotoxicity responses against 80%-

157 n was performed using an anti-human globulin-complement-dependent cytotoxicity technique.

158 nti-A2 and anti-B8,defined in a conventional complement-dependent cytotoxicity test (CDC).

159 recipients of failed cadaveric allografts by complement-dependent cytotoxicity tests and by an enzyme

160 nisms include antibody-, effector cell-, and complement-dependent cytotoxicity, the disruption of CD2

161 antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity through relief of immu

162 ong binding and mediated similarly effective complement-dependent cytotoxicity to GM2-expressing canc

163 We measured anti-pig IgM/IgG binding, and complement-dependent cytotoxicity to wild-type (WT), alp

164 -dependent inhibition of PDAC serum-mediated complement-dependent cytotoxicity towards cancer cells.

165 ytosis by Fc interactions with FcgammaRs and complement-dependent cytotoxicity upon IgG-Fc binding to

166 High complement-dependent cytotoxicity was associated with HA

167 ability to induce complement deposition and complement-dependent cytotoxicity when bound to several

168 Ofatumumab has enhanced capacity for complement-dependent cytotoxicity, whereas obinutuzumab,

169 Furthermore, antibody-mediated complement-dependent cytotoxicity with the antibodies se

170 y to predict T lymphocyte flow cytometry and complement dependent cytotoxicity XM results with the me

171 of donors at risk for positivity of flow- or complement-dependent cytotoxicity XM.